

# Betamethasone (0.05%) Ointment Formulation



Version Revision Date: SDS Number: Date of last issue: 13.09.2019 4.0 23.03.2020 1681976-00007 Date of first issue: 18.05.2017

#### **SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Betamethasone (0.05%) Ointment Formulation

Manufacturer or supplier's details

Company name of supplier : Organon & Co.

Address : Avenida 16 de Septiembre No. 301

Xaltocan - Xochimilco Mexico 16090

Telephone : 52 55 57284444 Emergency telephone : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

#### **SECTION 2. HAZARDS IDENTIFICATION**

**GHS Classification** 

Reproductive toxicity : Category 1B

Specific target organ toxicity

- repeated exposure

Category 1 (Pituitary gland, Immune system, muscle, thymus

gland, Blood, Adrenal gland)

**GHS label elements** 

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H360D May damage the unborn child.

H372 Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through

prolonged or repeated exposure.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust/ fume/ gas/ mist/ vapors/ spray.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P280 Wear protective gloves/ protective clothing/ eye protection/

face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.



# **Betamethasone (0.05%) Ointment Formulation**



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 4.0
 23.03.2020
 1681976-00007
 Date of first issue: 18.05.2017

Disposal:

P501 Dispose of contents/ container to an approved waste dis-

posal plant.

Other hazards

None known.

#### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	
Petrolatum	8009-03-8	>= 70 -< 90	
Propylene glycol monostearate	1323-39-3	>= 1 -< 5	
Betamethasone	378-44-9	>= 0.01 -< 0.1	

#### **SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

: May damage the unborn child.

delayed expo

Causes damage to organs through prolonged or repeated

exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.



# Betamethasone (0.05%) Ointment Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 4.0
 23.03.2020
 1681976-00007
 Date of first issue: 18.05.2017

Specific hazards during fire

fighting

Vapors may form explosive mixtures with air.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec: :

tive equipment and emergency procedures

Use personal protective equipment.

Follow safe handling advice and personal protective

equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for

containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not swallow.

Avoid contact with eves.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.



# Betamethasone (0.05%) Ointment Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 4.0
 23.03.2020
 1681976-00007
 Date of first issue: 18.05.2017

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents Organic peroxides

Explosives Gases

### **SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
Petrolatum	8009-03-8	VLE-PPT (Mist)	5 mg/m³	NOM-010- STPS-2014	
		TWA (Inhalable particulate matter)	5 mg/m³	ACGIH	
Propylene glycol monostearate	1323-39-3	VLE-PPT	10 mg/m <sup>3</sup>	NOM-010- STPS-2014	
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH	
		TWA (Respirable particulate matter)	3 mg/m³	ACGIH	
Betamethasone	378-44-9	TWA	1 μg/m3 (OEB 4)	Internal	
	Further information: Skin				
		Wipe limit	10 μg/100 cm <sup>2</sup>	Internal	

**Engineering measures** 

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Essentially no open handling permitted.



# **Betamethasone (0.05%) Ointment Formulation**



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 4.0
 23.03.2020
 1681976-00007
 Date of first issue: 18.05.2017

Use closed processing systems or containment technologies.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skip surfaces.

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : ointment

Color : white to off-white

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : > 93.3 °C

Evaporation rate : Not applicable

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower : No data available



# Betamethasone (0.05%) Ointment Formulation



Version Revision Date: SDS Number: Date of last issue: 13.09.2019 4.0 23.03.2020 1681976-00007 Date of first issue: 18.05.2017

flammability limit

Vapor pressure : No data available

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : Not applicable

#### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- : Vapors may form explosive mixture with air.

tions Can react with strong oxidizing agents.

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

### **SECTION 11. TOXICOLOGICAL INFORMATION**

## Information on likely routes of exposure

Skin contact Ingestion Eye contact

## **Acute toxicity**

Not classified based on available information.

### **Components:**

Petrolatum:



# Betamethasone (0.05%) Ointment Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 4.0
 23.03.2020
 1681976-00007
 Date of first issue: 18.05.2017

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Method: OECD Test Guideline 401

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Remarks: Based on data from similar materials

Propylene glycol monostearate:

Acute oral toxicity : LD50 (Mouse): > 5,000 mg/kg

Betamethasone:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

LD50 (Mouse): > 4,500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0.4 mg/l

Exposure time: 4 h

Skin corrosion/irritation

Not classified based on available information.

**Components:** 

Petrolatum:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Remarks : Based on data from similar materials

Propylene glycol monostearate:

Result : No skin irritation

Betamethasone:

Species : Rabbit

Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

**Components:** 

Petrolatum:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Remarks : Based on data from similar materials



# **Betamethasone (0.05%) Ointment Formulation**



Version Revision Date: SDS Number: Date of last issue: 13.09.2019 4.0 23.03.2020 1681976-00007 Date of first issue: 18.05.2017

Betamethasone:

Species : Rabbit

Result : No eye irritation

## Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

## Respiratory sensitization

Not classified based on available information.

### **Components:**

### Petrolatum:

Test Type : Buehler Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

#### Betamethasone:

Routes of exposure : Dermal
Species : Guinea pig
Result : Weak sensitizer

### Germ cell mutagenicity

Not classified based on available information.

### Components:

### Petrolatum:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Result: negative

Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection Method: OECD Test Guideline 474

Result: negative

Remarks: Based on data from similar materials

Betamethasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: positive



# **Betamethasone (0.05%) Ointment Formulation**



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 4.0
 23.03.2020
 1681976-00007
 Date of first issue: 18.05.2017

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse Application Route: Oral Result: equivocal

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

### Carcinogenicity

Not classified based on available information.

### **Components:**

### Petrolatum:

Species : Rat

Application Route : Ingestion

Exposure time : 2 Years

Result : negative

## Reproductive toxicity

May damage the unborn child.

#### Components:

### Petrolatum:

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening

test

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Skin contact

Result: negative

Remarks: Based on data from similar materials

#### Betamethasone:

Effects on fetal development : Species: Rabbit

Application Route: Intramuscular

Developmental Toxicity: LOAEL: 0.05 mg/kg body weight Result: Fetotoxicity., Malformations were observed.

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 0.42 mg/kg body weight

Result: Malformations were observed.

Species: Mouse

Application Route: Intramuscular

Developmental Toxicity: LOAEL: 1 mg/kg body weight



# Betamethasone (0.05%) Ointment Formulation



Version Revision Date: SDS Number: Date of last issue: 13.09.2019 4.0 23.03.2020 1681976-00007 Date of first issue: 18.05.2017

Result: Malformations were observed.

Reproductive toxicity - As-

sessment

: Clear evidence of adverse effects on development, based on

animal experiments.

## STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.

### Components:

## Betamethasone:

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood,

Adrenal gland

Assessment : Causes damage to organs through prolonged or repeated

exposure.

## Repeated dose toxicity

### **Components:**

## Petrolatum:

Species : Rat

NOAEL : 5,000 mg/kg
Application Route : Ingestion
Exposure time : 2 y

### Betamethasone:

Species : Rabbit
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 10 - 30 d

Target Organs : Pituitary gland, Immune system, muscle

Species : Rat
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Mouse
LOAEL : 0.1 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Dog

LOAEL : 0.05 mg/kg Application Route : Oral

Exposure time : 28 d

Target Organs : Blood, thymus gland, Adrenal gland



# Betamethasone (0.05%) Ointment Formulation

Version **Revision Date:** SDS Number: Date of last issue: 13.09.2019 23.03.2020 1681976-00007 Date of first issue: 18.05.2017 4.0

## **Aspiration toxicity**

Not classified based on available information.

### **Experience with human exposure**

### **Components:**

Betamethasone:

Inhalation Target Organs: Adrenal gland

Skin contact Symptoms: Redness, pruritis, Irritation

### **SECTION 12. ECOLOGICAL INFORMATION**

#### **Ecotoxicity**

## **Components:**

Petrolatum:

Toxicity to fish LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 203

Remarks: Based on data from similar materials

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10,000 mg/l

Exposure time: 48 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

NOEL (Pseudokirchneriella subcapitata (green algae)): >=

100 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 10 mg/l

Exposure time: 21 d

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Betamethasone:

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Americamysis): > 50 mg/l

Toxicity to algae/aquatic

plants

Exposure time: 96 h

EC50 (Pseudokirchneriella subcapitata (green algae)): > 34

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 34

mg/l



# Betamethasone (0.05%) Ointment Formulation



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 4.0
 23.03.2020
 1681976-00007
 Date of first issue: 18.05.2017

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.052 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

NOEC (Oryzias latipes (Japanese medaka)): 0.07 µg/l

Exposure time: 219 d

Method: OECD Test Guideline 229

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 8 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

# Persistence and degradability

#### **Components:**

Petrolatum:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 31 % Exposure time: 28 d

Method: OECD Test Guideline 301F

Remarks: Based on data from similar materials

#### Bioaccumulative potential

## **Components:**

Betamethasone:

Partition coefficient: n-

•

log Pow: 2.11

octanol/water Mobility in soil

No data available

Other adverse effects

No data available

#### **SECTION 13. DISPOSAL CONSIDERATIONS**

### **Disposal methods**

Waste from residues

Dispose of in accordance with local regulations.

Contaminated packaging

Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

## **SECTION 14. TRANSPORT INFORMATION**

## International Regulations

**UNRTDG** 



# Betamethasone (0.05%) Ointment Formulation



Version **Revision Date:** SDS Number: Date of last issue: 13.09.2019 23.03.2020 1681976-00007 Date of first issue: 18.05.2017 4.0

**UN** number **UN 3077** 

ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, Proper shipping name

N.O.S.

(betamethasone)

Class 9 Ш Packing group Labels 9

**IATA-DGR** 

UN 3077 UN/ID No.

Environmentally hazardous substance, solid, n.o.s. Proper shipping name

(Betamethasone)

Class 9 Packing group Ш

Miscellaneous, Labels

Packing instruction (cargo

aircraft)

Packing instruction (passen-

ger aircraft)

956

Environmentally hazardous yes

**IMDG-Code** 

**UN** number **UN 3077** 

Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

956

(Betamethasone)

Class 9

Subsidiary risk ENVIRONM.

Packing group Ш

Labels 9 (ENVIRONM.)

**EmS Code** F-A, S-F Marine pollutant yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

**Domestic regulation** 

NOM-002-SCT

**UN 3077** UN number

Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Betamethasone)

Class 9 Packing group Ш Labels 9

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### **SECTION 15. REGULATORY INFORMATION**

Safety, health and environmental regulations/legislation specific for the substance or mixture



# **Betamethasone (0.05%) Ointment Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 4.0
 23.03.2020
 1681976-00007
 Date of first issue: 18.05.2017

Federal Law for the control of chemical precursors, essential chemical products and machinery for

producing capsules, tablets and pills.

: Not applicable

## The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### **SECTION 16. OTHER INFORMATION**

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

NOM-010-STPS-2014 : Mexico. Norm NOM-010-STPS-2014 on Chemicals Polluting

the Work Environment - Identification, Assessment and Con-

trol - Appendix 1 Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average NOM-010-STPS-2014 / VLE- : Time weighted average limit value

PPT

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System



# **Betamethasone (0.05%) Ointment Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 4.0
 23.03.2020
 1681976-00007
 Date of first issue: 18.05.2017

Sources of key data used to compile the Material Safety

**Data Sheet** 

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 23.03.2020

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8